Pharmacokinetic trial of Medidur begins:
This article was originally published in Clinica
Executive Summary
Alimera Sciences and pSivida have kicked off the first human pharmacokinetic trial of Medidur, the companies' drug-eluting implant for the treatment of diabetic macular oedema. Medidur is injected intra-vitreally and delivers a very low dose of fluocinolone acetonide (FA), a corticosteroid, to the retina for up to three years. The new three-year study will also provide information on the location of Medidur FA in the eye after insertion and drug levels in the anterior chamber. Currently in a global phase III trial in around 900 patients, the device is the subject of a co-development agreement between Alimera, of Alpharetta, Georgia, and Perth, Australia-based pSivida.